Welcome to our dedicated page for 60 degrees pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 degrees pharmaceuticals stock.
60 Degrees Pharmaceuticals, Inc. (SXTP) is a clinical-stage company advancing novel therapies for infectious diseases, including its FDA-approved malaria prophylaxis ARAKODA. This news hub provides investors and healthcare stakeholders with verified updates on the company's scientific progress and operational developments.
Access timely announcements including clinical trial results, regulatory milestones, research partnerships, and strategic initiatives. Our curated collection ensures transparent tracking of SXTP's work in malaria prevention, tick-borne illness therapies, and antifungal/viral treatment pipelines.
Key updates cover FDA communications, trial phase transitions, academic collaborations, and market expansion efforts. The resource is particularly valuable for monitoring the company's progress in repurposing tafenoquine for emerging indications like babesiosis.
Bookmark this page for centralized access to SXTP's latest scientific advancements and corporate announcements. For comprehensive tracking of infectious disease treatment innovations, consider subscribing to our regulatory update alerts.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that a peer-reviewed, sponsored study at North Carolina State found Babesia infection in 24% of 50 patients presenting with chronic fatigue. The Company said these results support the theory that Babesia may prolong recovery in chronic fatigue and reinforce continuation of the B-FREE Chronic Babesiosis Study (NCT06656351), which is evaluating a 90-day ARAKODA (tafenoquine) regimen for resolution of severe fatigue. The B-Free study is enrolling at the Icahn School of Medicine at Mount Sinai in New York. The release notes that tafenoquine is approved in the U.S. for malaria prophylaxis as ARAKODA but is not proven or FDA-approved to treat or prevent babesiosis.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a planned expansion of sales and marketing for ARAKODA after a 6-month commercial pilot showed increasing product sales among prescribers. Plans for 2026 include doubling inside sales representatives, a new GoodRx partnership to broaden point-of-sale visibility, and an enhanced digital "surround sound" marketing campaign to boost prescriber awareness and engagement.
Separately, the company will add at least two babesiosis clinical sites for ongoing randomized and expanded-access studies following FDA feedback on its Breakthrough Therapy designation request; FDA declined the request but acknowledged babesiosis as serious and suggested resubmission with controlled-trial data. Tafenoquine (ARAKODA) remains approved for malaria prophylaxis and is not approved for babesiosis treatment.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) opened the central site at Mount Sinai Icahn School of Medicine to enroll patients in the B-FREE Chronic Babesiosis Study on Nov 21, 2025.
The Phase 2 open-label study (NCT06656351) will evaluate an ARAKODA® (tafenoquine) regimen over 90 days for resolution of severe fatigue and parasite eradication, will run ~12 months, and plans to enroll up to 100 patients. Internal estimates put the U.S. unmet need between 4,400 and 190,000 cases annually; a study aim is to confirm Babesia infection using validated molecular tests to refine market size. Tafenoquine is approved for malaria prophylaxis as ARAKODA® but is not approved or proven for babesiosis treatment.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2025 results for the quarter ended September 30, 2025. Net product revenue rose 223% YoY to $438,000 and ARAKODA pharmacy deliveries increased 14% to 1,505 boxes. The company recorded a gross loss of ~$100,000 versus a $24,000 gross profit a year earlier due to a one-time inventory write-off tied to short shelf-life validation lots. Operating expenses were ~$2.32 million, driven by an additional $367,000 in advertising and sales promotion. Net loss attributable to common shareholders was approximately $2.44 million or ($0.66) per share. New four-year shelf-life lots are expected to enter the supply chain in early Q1 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that the first patient completing its expanded access study of ARAKODA® (tafenoquine) for relapsing babesiosis tested negative for Babesia by both a Mayo Clinic RT-PCR and an FDA-licensed RNA amplification assay that is described as at least 100x more sensitive than standard RT-PCR.
On October 3, 2025 the company submitted a Breakthrough Therapy request to FDA and plans a Type B meeting in early 2026 to discuss requirements for a supplementary NDA; remaining patients are expected to finish between January and October 2026 and clinical data are expected in second half of 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) named its chronic babesiosis Phase 2 trial the B-FREE Chronic Babesiosis Study (NCT06656351). The open-label study will begin in early November and run for approximately 12 months, testing a 90-day ARAKODA® (tafenoquine) regimen for resolution of severe fatigue and parasite eradication in chronic babesiosis. No FDA-approved or society-recommended treatment for chronic babesiosis currently exists. The company donated $5,000 split between Global Lyme Alliance and ILADEF after a patient-driven naming contest.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), a pharmaceutical company focused on vector-borne disease treatments, has announced an updated schedule for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation, and the management team will be available for one-on-one meetings during the conference. The presentation will be accessible via webcast for interested investors.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a company focused on developing medicines for vector-borne diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation on September 10 at 2:30 ET. Management will also conduct one-on-one meetings during the conference. The presentation will be available via webcast with replay access for approximately 90 days on the company's investor relations website.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has selected the Icahn School of Medicine at Mount Sinai as the central site for a Phase II clinical trial evaluating tafenoquine for chronic babesiosis treatment. The 90-day open-label study will assess the drug's efficacy in treating patients with disabling fatigue lasting at least six months.
The trial will evaluate ARAKODA® (tafenoquine) with a dosing regimen of 2 x 100 mg tablets administered orally for the first four days, followed by weekly doses for 12 weeks. The primary endpoint is fatigue resolution measured using a patient-reported outcome scale. Enrollment is expected to begin in Q4 2025 with completion targeted for Q2 2026.
This study is one of three clinical trials sponsored by 60 Degrees Pharma to evaluate tafenoquine for babesiosis, with data expected in H1 2026. The company plans to submit a New Drug Application (NDA) to the FDA in 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2025 financial results, highlighting a 19% year-over-year decline in net product revenues to $101,000 due to a temporary supply chain disruption. Despite lower revenues, the company achieved increased profitability with a gross profit of $51,000, up from $35,000 in Q2 2024.
Operating expenses decreased significantly to $1.86 million from $4.22 million in Q2 2024. The net loss improved to $1.84 million ($1.25 per share) compared to $4.29 million ($21.12 per share) in Q2 2024. With $1.97 million cash on hand and recent public offering proceeds of $4.46 million, the company projects runway through March 31, 2026.
Research studies indicate the total addressable U.S. market for ARAKODA for human babesiosis could reach $1.1 billion over the remaining 10-year patent life, with annual babesiosis incidence estimated between 25,000-380,000 cases.
FAQ
What is the current stock price of 60 degrees pharmaceuticals (SXTP)?
What is the market cap of 60 degrees pharmaceuticals (SXTP)?
